pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
ELI LILLY CO · news · pharmadog
← back to ELI LILLY CO
News mentioning ELI LILLY CO
625
stories
11h
For Lilly, cash-pay is key in the US and, increasingly, abroad
endpoints
15h
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
17h
LENZ cuts 75% of staff as third quarter earnings disappoint
biospace
18h
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
19h
Eli Lilly scraps phase 2 Alzheimer's program after drug falls short of expectations
fiercebiotech
19h
Lilly again far surpasses revenue expectations
endpoints
1d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
1d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
1d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
1d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
1d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
1d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
1d
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
endpoints
1d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
1d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
2d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
2d
5 new drug launches that defied industry expectations
biospace
2d
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
stat
2d
Lilly's ads can continue after Novo challenge, judge rules
endpoints
2d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
2d
Alphabet’s GV is one of biotech’s most influential corporate investors
biospace
2d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
3d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
3d
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq
fiercebiotech
3d
Lilly’s music-loving, intense lead dealmaker knows what he wants
endpoints
5d
#ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancer
endpoints
6d
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
biospace
7d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
7d
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
7d
Roche affirms sales outlook amid doubts about its future
biopharma dive
← prev
page 1 of 21
next →
